Skip to Content
 

VICC toll-free number 1-877-936-8422

Urologic / Genitourinary Cancers

The Urologic Oncology Program offers an integrated, comprehensive, multidisciplinary approach to the treatment of all genitourinary malignancies, with a special emphasis on providing patients with innovative therapies derived from cutting-edge basic research.

Clinical Trials for Urologic / Genitourinary Cancers

22 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Ancillary

Prostate

VICCURO15140

01/18/2016

Analysis of Cell-Free DNA (cfDNA) in Men with Elevated PSA Levels

Basic Science

Bladder

VICCURO1322

03/28/2014

Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

Health Services Research

Prostate

VICCURO1638

06/29/2015

Patient-Centered Treatment Decision-Making in Advanced Prostate Cancer

Other

Prostate

URO70807-M

05/10/2012

Men's Eating and Living Study: A Randomized trial of diet to alter disease progression in prostste cancer patients on active surveillance

Treatment

Kidney (Renal Cell)
Lung
Melanoma
Miscellaneous
Non Small Cell
Ovarian
Uterine

VICCPHI1676

11/04/2016

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

Treatment

Kidney (Renal Cell)
Lung
Melanoma
Miscellaneous
Non Small Cell
Uterine

VICCPHI1634

08/30/2016

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

Treatment

Bladder
Urologic

VICCURO15119

06/14/2016

Phase II Trial of Palbociclib (PD-0332991) in Patients with Metastatic Urothelial Cancer (UC) after Failure of First-Line Chemotherapy

Treatment

Kidney (Renal Cell)

VICCURO15127

06/01/2016

A Randomized Phase 2 Trial of AXITINIB and TRC105 versus AXITINIB Alone (Including a Lead-In Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma

Treatment

Bladder
Colon
Gastric/Gastroesophageal
Kidney (Renal Cell)
Rectal
Urologic

VICCGI15126

05/03/2016

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

Treatment

Prostate

NRGUROR0924

03/10/2016

Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Treatment

Bladder

NRGUROGU001

02/29/2016

Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer

Treatment

Bladder

ECOGUROS1314

01/18/2016

A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

Treatment

Bladder
Breast
Colon
Esophageal
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Lung
Melanoma
Non Small Cell
Pancreatic
Rectal
Urologic
Uterine

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

Bladder
Breast
Hematologic
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Pancreatic
Urologic

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Treatment

Bladder
Urologic

ECOGUROEA8141

08/27/2015

A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

Treatment

Prostate

VICCURO1540

07/08/2015

A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men with High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy. MDV3100-13

Treatment

Prostate

VICCURO1473

01/09/2015

A Randomized Phase II Study of Androgen Deprivation Therapy with or without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer.

Treatment

Prostate

CTSUALLIANCEURO031201-M

11/21/2014

URO A031201: Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Treatment

Prostate

VICCURO1450

08/13/2014

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Treatment

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

Prostate

CTSUUROS1216-M

01/16/2014

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Treatment

Prostate

CTSUUROC90203-M

11/05/2007

A randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer